ESMO 2025 Insights

Report/eBook

2025 Post-ESMO Oncology Sample Report

The 2025 ESMO Congress delivered a record volume of clinical data, with over 3,000 abstracts and 100+ late-breaking presentations. This exclusive report sample from Biomedtracker and Datamonitor Healthcare distills the most impactful developments, highlighting the trials, assets, and companies poised to reshape the oncology landscape. What’s Inside the Sample Report? Strategic analysis of late-breaking ESMO […]

November 6, 2025

Download today

I would like to receive Evaluate industry & market reports, and the latest news from Evaluate. エバリュエートの業界・市場レポートやイベント等最新ニュースを受け取る（無料）

Connect with our advisory team
Get insights on BD&L, portfolio, and competitive intelligence 業界特化型コンサルタントとの個別相談を希望する
BD&L／ポートフォリオ／競合インテリジェンスについて、担当者よりご連絡いたします

Your information will be used in accordance with our Privacy notice. ご提供いただいた情報は、当社のプライバシー通知に基づき適切に取り扱います。

The 2025 ESMO Congress delivered a record volume of clinical data, with over 3,000 abstracts and 100+ late-breaking presentations.

This exclusive report sample from Biomedtracker and Datamonitor Healthcare distills the most impactful developments, highlighting the trials, assets, and companies poised to reshape the oncology landscape.

What’s Inside the Sample Report?

Strategic analysis of late-breaking ESMO 2025 data
LOA changes and commercial outlooks for 50+ oncology programs
Expert commentary on trial design, biomarker strategies, and SoC disruption

Upcoming Webinar

World Preview 2026

Tuesday 16th June 2026 | 3pm BST

By 2032, the global pharmaceutical market is forecast to reach almost $1.9tn. Inside the innovations, dealmaking, and portfolio strategies transforming the global biopharma pipeline.

Frequently Asked Questions

1. What are the key oncology trends highlighted in the 2025 Post-ESMO Report?

The report identifies pivotal clinical trial readouts, emerging therapeutic modalities, and shifts in standard of care across major tumor types. It also explores the strategic implications of these developments for business development, licensing, and portfolio planning.

How can this report support BD&L and portfolio strategy teams?

By providing expert analysis of late-breaking data and updated likelihood of approval (LOA) metrics, the report helps BD&L and strategy teams assess asset competitiveness, identify partnering opportunities, and refine investment priorities.

Which companies and assets are featured in the report?

The report covers data from leading pharma and biotech companies presented at ESMO 2025, including updates on high-impact assets across bladder, breast, lung, gastric, and other cancers. It includes LOA changes and commercial outlooks for over 50 oncology programs.

Core Forecasting Products

Regional Forecasts

Forecast Enablement

Bespoke Forecasting

Portfolio & Scenario Analysis

Competitive Context

Pipeline & Asset Intelligence

Deal and Asset Evaluation

Bespoke Business Development Analysis

Scientific & Pipeline Intelligence

Competitive Intelligence Platforms

Epidemiology Context

Market and Company Benchmarks

Custom Solutions

Support

Training and Enablement

Need Help?

Forecasting

Business Development & Licensing

Portfolio Strategy

Competitive Intelligence

Discover Resources

Report/eBook

2025 Post-ESMO Oncology Sample Report

Download today

The 2025 ESMO Congress delivered a record volume of clinical data, with over 3,000 abstracts and 100+ late-breaking presentations.

Upcoming Webinar

World Preview 2026

Tuesday 16th June 2026 | 3pm BST

Frequently Asked Questions

1. What are the key oncology trends highlighted in the 2025 Post-ESMO Report?

How can this report support BD&L and portfolio strategy teams?

Which companies and assets are featured in the report?

Related Content

Discover

Discover

Discover

Discover

Discover

Discover

Discover

Discover

Discover

Discover